PCSK9
可欣
低密度脂蛋白受体
低密度脂蛋白受体相关蛋白8
炎症
载脂蛋白B
脂蛋白
调节器
前蛋白转化酶
载脂蛋白E
胆固醇
受体
生物
内科学
内分泌学
化学
极低密度脂蛋白
免疫学
生物化学
医学
基因
疾病
作者
Xueqin Bai,Juan Peng,Meimei Wang,Jun Xiao,Qiong Xiang,Zhong Ren,Hongyan Wen,Zhi‐Sheng Jiang,Zhi‐Han Tang,Lu‐Shan Liu
标识
DOI:10.1016/j.cca.2018.04.040
摘要
Atherosclerosis is characterized by chronic inflammation and lipid accumulation in arterial walls, resulting in several vascular events. Proprotein convertase subtilisin kexin 9 (PCSK9), a serine protease, has a pivotal role in the degradation of hepatic low-density lipoprotein receptor (LDLR). It can increase plasma concentrations of low-density lipoprotein cholesterol and affect lipid metabolism. Recently, PCSK9 has been found to accelerate atherosclerosis via mechanisms apart from that involving the degradation of LDLR, with an emerging role in regulating the inflammatory response in atherosclerosis. Apolipoprotein E receptor 2 (apoER2), one of the LDLR family members expressed in macrophages, can bind to its ligand apolipoprotein E (apoE), exhibiting an anti-inflammatory role in atherosclerosis. Evidence suggests that apoER2 is a target of PCSK9. This review aims to discuss PCSK9 as a potential regulator of apoE/apoER2 against inflammation in atherosclerosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI